Update on IBS and CIC Abstracts and Insight From DDW 2014

Slides:



Advertisements
Similar presentations
IBS and the Low FODMAP Diet
Advertisements

HIGH VALUE CARE GI CONDITIONS CHRONIC DIARRHEA EDWARD LEVINE MD OSUWMC OCTOBER 11, 2014.
Case Studies in Luminal Gastroenterology Adam Harris Consultant Gastroenterologist The Spire Tunbridge Wells Hospital.
Welcome! Colon Health, it’s not just about Cancer. Philip N Styne, MD AGAF Medical Director Digestive Health Center.
The Human Body: From Food to Fuel BIOL 103, Chapter 4 (Part 2)
FODMAPS: a review of the current literature and more… Michael Bizeau, PhD Metropolitan State University of Denver.
Phase Difference = Phase Difference = 0.05.
By: Raymond Payne Elizabeth Bentz Holly Sebring & Megan Schweller.
COMMON OPD PATIENT. 29 y.o. lady 18 month history loose stool  2-3 per day  Begins just soft, then looser –”explosive”  Night ok  No blood, occasional.
肠胃道易激综合症 (IBS) 对食物的过敏 及 饮食控制 黄光明医生 副顾问 国大医院 黄光明医生 副顾问 国大医院.
Constipation. Different definitions of constipation have been used in clinical studies → difficulty in characterizing the problem. –< 3 stools / week.
 Celiac disease is an immune reaction to eating gluten, a protein found in wheat, barley and rye.  If you have celiac disease, eating gluten triggers.
Jackie Skradski Pharm.D. Candidate 2016 Ferris State University College of Pharmacy February 25, 2015.
Appendicitis inflammation of appendix can result in peritonitis or septicemia.
Shad Johnson MPAS, PA-C Southeast Idaho Gastroenterology.
Division of Gastroenterology
Irritable Bowel Syndrome
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
A Clinical Overview.
Compliant with neg bx (6) Compliant with pos bx (3)
CLINICAL USE AND EFFICIACY IN IBS
Diagnosis and Treatment of IBS
Volume 45, Pages (January 2018)
The Effects of a Low-FODMAP Diet on Treatment of Irritable Bowel Syndrome in Patients Melanie Palmer.
Image Challenge Q: What underlying disease is most likely to have been present in this patient? 1. Atrial fibrillation 2. Chronic constipation 3. Chronic.
Symptoms & Treatment of Irritable Bowel Syndrome (IBS)
Timely Diagnosis of Gastroenteritis: Implications for Patients and Public Health.
IBS-D -- From Diagnosis to Management
Incorporating New Therapies in IBS-C
Management of Sepsis in the PICU
Diet as a Therapy for Irritable Bowel Syndrome: Progress at Last
iPad Instructions iPad Instructions Polling Question.
Pathophysiology of Irritable Bowel Syndrome
Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.
A Practical Application for Students With GI Upset
1.FODMAPs* enter the small bowel.
Disclaimer. LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL.
Reducing Postoperative Ileus
Extended Half-life Factor Products in the Management of Hemophilia
IRRITABLE BOWEL SYNDROME
More Than Treatment.
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
CME Evening – 15 August 2018.
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.
Rome IV: What Has Changed? Rome IV IBS Subtypes.
The Heart Failure Team Heart Failure Care Map First 24 hours.
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
The JAK-STAT Pathway and Graft-vs-Host Disease
Battling Constipation
Using Heart Rate as a Biomarker in Clinical Practice.
Children’s Hospital Update
Volume 155, Issue 4, Pages (October 2018)
Overcoming Clinical Inertia
Updates in the Management of Parkinson's Disease Psychosis
Updates in the Management of Acute Promyelocytic Leukemia
Extended Half-life Factor Products in the Management of Hemophilia
Severe Asthma and Comorbidities
Signal Conditioning.
Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis  Elizabeth J. Videlock, Vivian.
Managing Pain in the 21st Century
Contemporary Considerations in Biomarker-Guided Therapy
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
Irritable Bowel Syndrome (IBS)
Going Beyond EXTREME in Head and Neck Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Irritable bowel syndrome
Comparative Studies of Biologics in Ulcerative Colitis
Autoantibodies to amylase at CD diagnosis and after gluten-free diet, compared with autoantibody concentration detected in healthy and celiac control groups.
Presentation transcript:

Update on IBS and CIC Abstracts and Insight From DDW 2014

Biomarkers in IBS

Biomarker Meta-Analysis Results

Colonic Bacterial Fermentation

Colonic Bacterial Fermentation: Methods

Colonic Bacterial Fermentation: Results

Low-FODMAP and Gluten-Free Diet in IBS

Low-FODMAP and Gluten-Free Diet in IBS: Methods

Low-FODMAP and Gluten-Free Diets in IBS: Results

Low-FODMAP Meta-Analysis

FODMAP Meta-Analysis: Methods and Results

GC-C/cGMP Signaling

GC-C/cGMP Signaling: Methods and Results

Linaclotide Phase 3b Results

Effect of Linaclotide on Bloating

GI Prescribing for Chronic Constipation

GI Prescribing for Chronic Constipation: Results

Eluxadoline in IBS-D, Phase 3

Eluxadoline in IBS-D, Phase 3: Methods

Eluxadoline in IBS-D, Phase 3: Results

Abbreviations

References

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.